QRL: Multiple Use Blood Lancet For Single Patient Use Only

Product code QRL, “Multiple Use Blood Lancet For Single Patient Use Only” in FDA's classification database, is a Class II device type under 21 CFR 878.4850 (blood lancets), reviewed by FDA's General, Plastic Surgery panel. FDA's 510(k) database lists 27 clearances under QRL, 27 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
QRL
Regulation
21 CFR 878.4850
Class
II
Panel
General, Plastic Surgery
Clearances
27
Most recent
Aug 18, 2026
Median review, last 2 years
40 days
Third-party review
Not eligible
Implant
No

What it covers

A multiple use capable blood lancet intended for use on a single patient that is comprised of a single use blade attached to a solid, reusable base that is used to puncture the skin to obtain a drop of blood for diagnostic purposes.

FDA’s definition of product code QRL, from the Product Classification database.

Recent clearances

510(k)DeviceApplicantDecisionType
K262135Lancing deviceTianjin Huahong Technology Co., Ltd.Aug 18, 2026Traditional
K262211LancetTianjin Huahong Technology Co., Ltd.Jul 22, 2026Special
K260122Lancing Device (PressGo, LDE3, LDE3AST, LDE5, EasyStep)SteriLance Medical (Suzhou), Inc.Jul 6, 2026Traditional
K253706Lancing device (HH-XV-T)Tianjin Huahong Technology Co., Ltd.Dec 9, 2025Special
K250813MICROLET®NEXT 2 Lancing DeviceAscensia Diabetes Care U.S., Inc.May 14, 2025Traditional
K243306Lancet (IA, IB, IC, ID, IE, IK, IL, IM, IIA, IIB, III, V, VI, VII, VIII, IX); Lancing device (HH-X-T, HH-XV-T, HH-XVI-T, HH-XVII-T, HH-XVIII-T, HH-XIX, HH-XXI-T, HH-XXII-T, HH-XXIII-T, HH-XXIV-T, HH-XXV-T, HH-XXVI-T, HH-XXVIII-T, HH-XXIX-T, HH-XXX-T, HH-XIII-T, HH-XXVII-T)Tianjin Huahong Technology Co., Ltd.Nov 15, 2024Special
K232912Facet Aurora Reusable Lancet BaseFacet Technologies, LLCJan 25, 2024Traditional
K231797Medifun Lancing Device, Model No. LD-E1Medifun CorporationNov 22, 2023Traditional
K223643Verifine® Ease Lancing Device, Verifine® Lancing DevicePromisemed Hangzhou Meditech Co., Ltd.Feb 21, 2023Traditional
K221419TD-5010 Lancing Device and TD-5084 Sterile LancetsGostar Co., Ltd.Jan 20, 2023Traditional
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 27 with a free account)

Clearances by year

27 QRL 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)354
2025237
2024277
20233155
20221791

Who submits

18 applicants cleared a QRL device since 2011. 44% of the clearances went to applicants in China, then United States (30%), Taiwan (11%) and Japan (7%). By type: Traditional 89% and Special 11%.

ApplicantClearances since 2011
Tianjin Huahong Technology Co., Ltd.5
Facet Technologies, LLC3
Ascensia Diabetes Care U.S., Inc.2
Roche Diabetes Care, Inc.2
SteriLance Medical (Suzhou), Inc.2
Arkray, Inc.1
Asahi Polyslider Co., Ltd.1
Beijing Ruicheng Medical Supplies Co., Ltd.1

How FDA classifies it

(b) Single use only blood lancet without an integral sharps injury prevention feature—(1) Identification. A disposable blood lancet intended for a single use that is comprised of a single use blade attached to a solid, non-reusable base that is used to puncture the skin to obtain a drop of blood for diagnostic purposes.

(2) Classification. Class II (special controls). The special controls are:

(i) The design characteristics of the device must ensure that the structure and material composition are consistent with the intended use and address the risk of sharp object injuries and bloodborne pathogen transmissions.

(ii) Mechanical performance testing must demonstrate that the device will withstand forces encountered during use.

(iii) The device must be demonstrated to be biocompatible.

(iv) Sterility testing must demonstrate the sterility of any device component that breaches the skin (e.g., blade).

(v) Labeling must include:

(A) Detailed descriptions, with illustrations, of the proper use of the device.

(B) Handwashing instructions for the user before and after use of the device.

(C) Instructions on preparation (e.g., cleaning, disinfection) of the skin to be pierced.

(D) Instructions for the safe disposal of the device.

(E) Labeling must be appropriate for the intended use environment.

(1) For those devices intended for health care settings, labeling must address the health care facility use of these devices, including how these lancets are to be used with personal protective equipment, such as gloves.

(2) For those devices intended for use in the home, labeling must be written so that it is understandable to lay users.

(vi) Labeling must also include the following statements, prominently placed:

(A) “For use only on a single patient. Discard the entire device after use.”

(B) “Warning: Not intended for more than one use. Do not use on more than one patient. Improper use of blood lancets can increase the risk of inadvertent transmission of bloodborne pathogens, particularly in settings where multiple patients are tested.”

From 21 CFR 878.4850. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 878.4850 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent QRL clearances declared.

Ask about QRL

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about QRL

What is FDA product code QRL?

Product code QRL, “Multiple Use Blood Lancet For Single Patient Use Only” in FDA's classification database, is a Class II device type under 21 CFR 878.4850 (blood lancets), reviewed by FDA's General, Plastic Surgery panel. FDA's 510(k) database lists 27 clearances under QRL, 27 of them since 2011.

How many 510(k) clearances are there under QRL?

FDA’s 510(k) database listed 27 clearances under QRL as of Oct 29, 2026, 27 of them decided since 2011; the most recent decision was Aug 18, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a QRL 510(k)?

For the 6 QRL clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 40 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most QRL clearances?

Since 2011: Tianjin Huahong Technology Co., Ltd. (5), Facet Technologies, LLC (3), Ascensia Diabetes Care U.S., Inc. (2), Roche Diabetes Care, Inc. (2) and SteriLance Medical (Suzhou), Inc. (2). 18 applicants have cleared a QRL device in that time.

Sources

  1. FDA product classification: QRL · Product Classification database
  2. 21 CFR 878.4850: Blood lancets · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for QRL · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow QRLGet an email when FDA clears, recalls or publishes guidance for QRL devices.

Know what FDA already cleared.